You are more game than I.
The old had problems, the new still has the same problems. They just dont go away.
CYP is only getting in line if MSB fail to get approval.
The trial that CYP has put forward is a very good indication that they know they would not be able to match effecacy to MSB .
Ann: Strategic Review of Cynata Clinical Development Portfolio, page-14
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.005(1.82%) |
Mkt cap ! $48.78M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 26.5¢ | $71.17K | 257.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 145786 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |